Tag: Abbott

The Europe defibrillator market, valued at USD 3.87 billion in 2024, is projected to reach USD 7.23 billion by 2033, with a CAGR of 7.2%. Growth drivers include rising cardiovascular diseases, technological advancements, and government initiatives to expand public defibrillator access. Key segments include implantable and external defibrillators with significant usage in hospitals, public, and home settings. The market faces challenges such as high device costs and regulatory complexities. Leading players like Medtronic and Philips are instrumental in market expansion through innovations and strategic partnerships across Europe.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Inferior Vena Cava IVC Filter Market size & share revenue was valued at approximately USD 895.82 Million in 2024 and is expected to reach USD 974.16 Million in 2025 and is expected to reach around USD 2,094.10 Million by 2034, at a CAGR of 8.88% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Canon Medical Systems, Cardinal Health, Cook, Esaote SpA, General Electric Company, Hologic, Inc., Koninklijke Philips N.V., Samsung Healthcare, Shimadzu Corporation, Siemens Healthcare Private Limited, Stryker, Terumo Europe NV and others.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach around USD 2,943.92 Million by 2034, at a CAGR of 16.65% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Artivion Inc., Athersys Inc., Baxter International Inc., Cellular Logistics Inc., Elutia Inc., Heartseed Inc., Medtronic Plc, Merck kGaA, Mesoblast Ltd., Neoolife Inc., Tejiin Limited, Terumo Corporation, and W.L. Gore & Associates, Inc and others.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), PepGen (PEPG), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their Options